The prognosis of relapsed acute myeloid leukaemia (AML) is poor and treatment is challenging. While the most potent treatment modality for patients who achieve a complete remission after relapse is still allogeneic haematopoietic cell transplantation (allo-HCT), both transplant-related mortality and relapse rates are high and many patients are not candidates for this approach. After a few decades of relative stasis in this field, a large number of novel approaches have become available to tackle this highly fatal disease. This is mostly due to our improved understanding of disease pathogenesis (including targetable mutations) and the anti-leukaemia potential of the immune system. Several small-molecule inhibitors and immunotherapeutic options are being explored in clinical trials and many more are in pre-clinical phase. Future studies will focus on novel and mechanistically driven combinations, sequential treatments, and low-toxicity maintenance strategies. While cure of relapsed/refractory AML without allo-HCT is currently unlikely, treatments are becoming less toxic and remissions are lasting longer.
The management of acute myeloid leukaemia (AML) relapse in adults continues to remain a major therapeutic challenge despite the increasing availability of novel agents including targeted therapies (Thol et al, 2015) . When considering treatment options for patients with relapsed/refractory AML, patient-and disease-related factors [e.g., age, comorbidities, performance status, cytogenetic and molecular abnormalities, prior lines of chemotherapy, history of prior allogeneic haematopoietic cell transplant (allo-HCT), and time to relapse after previous complete remission (CR)] should be carefully evaluated (Weltermann et al, 2004; Breems et al, 2005; Thol et al, 2015) . Relapsed AML must be considered differently in two broad categories: (i) relapse before allo-HCT, and (ii) relapse after allo-HCT. Generally, the current curative-intent strategies for managing patients prior to allo-HCT revolve around the same goal of achieving a CR to proceed with allo-HCT in fit patients. In contrast, there is no standard curative-intent strategy for post-HCT relapse and a variety of palliative approaches exists -all with the goal of achieving a durable remission. Table I summarizes the phase 2 or 3 clinical trials discussed herein.
Relapse before allogeneic haematopoietic cell transplantation

Chemotherapy
Although multiple chemotherapy combinations have been explored over the past 2-3 decades, there is still no standard cytoreductive regimen for the treatment of patients with relapsed or refractory AML (Amadori et al, 1991; Visani et al, 1994; Pastore et al, 2003; Ravandi et al, 2010; Becker et al, 2011; Faderl et al, 2012) . Commonly used salvage chemotherapy regimens for younger patients not responding to initial induction chemotherapy include FLAG-IDA (fludarabine, cytarabine, idarubicin and granulocyte colony-stimulating factor (Steinmetz et al, 1999; Pastore et al, 2003; Bergua et al, 2016; Delia et al, 2017) and MEC (mitoxantrone, etoposide and cytarabine) (Amadori et al, 1991; Spadea et al, 1993; Greenberg et al, 2004 ) with reported CR rates ranging from 40% to 65%. Nonetheless, allo-HCT is the only potential curative therapy for patients achieving second CR (CR2), and therefore it should be considered for all eligible candidates (Burnett et al, 2013) . Responses to salvage chemotherapy are lower for older adults (~30%), likely not only due to age per se, but also due to higher-risk disease biology with adverse cytogenetic and molecular abnormalities (Sarkozy et al, 2013) .
In older patients or those unfit for intensive salvage chemotherapy, hypomethylating agents (HMAs) can induce a CR in about 20% of cases with a median survival of 7-9 months (Ivanoff et al, 2013; Ritchie et al, 2013; Itzykson et al, 2015) . Responses to HMAs are even less frequent in patients relapsing after allo-HCT, with a recent prospective study in 39 patients relapsing within 100 days of transplantation showing 30% overall response rate [ORR; CR + CR with incomplete blood count recovery (CRi)] to azacitadine and a CR rate of only 7Á7% (Woo et al, 2017) . Addition of vosaroxin to cytarabine compared to cytarabine plus placebo in a randomized phase III trial showed a higher CR rate (30% vs. 16%, P < 0Á01) for vosaroxin/cytarabine among all study patients and an improved median overall survival (OS) only for patients >60 years old (7 months vs. 5 months, P = 0Á003) . Given the overall poor outcomes with currently available chemotherapy options, participation in clinical trials should be encouraged in all elderly and unfit patients with relapsed/refractory AML.
Allogeneic haematopoietic cell transplantation
Allo-HCT is best performed in CR, which is preferred by allowing enough time for a robust graft-versus-leukaemia (GVL) effect to be established. Results may be even better in patients with a deeper remission documented by negative cytogenetic, molecular or flow cytometric analyses, although direct evidence for the additional value of minimal residual disease negativity in CR2 is lacking. In contrast, allo-HCT in patients with active leukaemia at the time of transplant historically yielded poor outcomes with long-term survival rates of only about 20% (Clift et al, 1992; Schmid et al, 2006; Duval et al, 2010; Jabbour et al, 2014; Othus et al, 2015) . Encouraging long-term outcomes were recently reported in patients with primary induction failure receiving fludarabine, amasacrine, cytarabine followed by immediate reduced-intensity conditioning (RIC) allo-HCT resulting in long-term survival rates of 35-45% (Schmid et al, 2006; Holtick et al, 2016) . Another study using 131 I-anti-CD45 antibody followed by RIC allo-HCT in patients with advanced AML/myelodysplastic syndrome (MDS) reported a promising 1-year OS rate of 40% (Pagel et al, 2009) . However, there are only a few such studies with acceptable outcomes in patients undergoing allo-HCT with active disease and thus this approach is not recommended outside of a clinical trial.
Relapse after allogeneic haematopoietic cell transplantation
Relapse after allo-HCT remains a major obstacle with 1-year post-relapse OS of~20% (Schmid et al, 2012; Bejanyan et al, 2015) . Although several therapeutic options are available for relapsed AML after transplantation, only a minority of patients survive long-term. A recent analysis by the Center for International Blood and Marrow Transplant Research (CIBMTR) identified several risk factors [shorter time to relapse post-HCT, age > 40 years, adverse cytogenetics, unrelated donor, and evidence of active graft-versus-host disease (GVHD) at the time of relapse] as significantly associated with worse survival (Bejanyan et al, 2015) . In addition, higher leukaemia burden at the time of relapse negatively affects survival (Schmid et al, 2012) . Outcomes were better for patients with later relapse (>6 months post-HCT) and particularly in those who received subsequent cell-based therapy with either donor lymphocyte infusion (DLI) or second allo-HCT. In contrast, survival was the worst in patients having leukaemia relapse within 6 months of transplantation, with only <5% being alive at 1 year after relapse. Strategies that are commonly used to treat AML relapse after transplantation include withdrawal of immunosuppression, DLI with or without cytoreductive chemotherapy/HMAs, second allo-HCT, targeted therapies, and clinical trials.
Withdrawal of immunosuppression
Withdrawal of immunosuppression in patients with AML relapse is used to enhance GVL activity. Although there are no standards for managing patients with relapsed AML, most clinicians start with a brisk taper of immunosuppression (over 1-3 weeks) with cautious observation for GVHD, before any additional relapse-directed interventions (Bishop et al, 2010) . Withdrawal of immunosuppression alone, however, only occasionally results in CR or durable long-term leukaemia-free survival, with most studies reporting only 4-7% CR using this intervention alone (Oran et al, 2007; Bejanyan et al, 2014) . The efficacy of immunosuppression taper on leukaemia control may vary depending on the intensity of the conditioning regimen used prior to allo-HCT. In one report, withdrawal of immunosuppression in patients with early relapse after RIC transplantation resulted in durable long-term remissions in up to two-thirds of patients, although most patients had lymphoid malignancies (Kekre et al, 2015) . In contrast, most studies report disappointing outcomes in patients with early AML relapse after alloHCT, particularly for those after myeloablative conditioning, regardless of the type of interventions used for leukaemiadirected therapy (Mielcarek et al, 2007; Bejanyan et al, 2015) . The major limitation of immunosuppression withdrawal is the increased risk of severe GVHD that is observed in >50% of cases (Elmaagacli et al, 1999; Kekre et al, 2015) , which can preclude subsequent use of cell-based therapies with DLI or second transplant. The median time to developing GVHD after withdrawal of immunosuppression is about 30 days (Kekre et al, 2015) , therefore close monitoring for any signs or symptoms of GVHD is warranted before DLI is performed.
Donor lymphocyte infusion
Donor lymphocyte infusion is frequently used in AML patients relapsing after allo-HCT, particularly those receiving human leucocyte antigen-identical sibling donor transplant. The goal of this strategy is to enhance the GVL effect through infusion of non-tolerant donor T cells without GVHD pharmacological prophylaxis (Schmid et al, 2007 (Schmid et al, , 2012 Warlick et al, 2012; Bejanyan et al, 2014 Bejanyan et al, , 2015 He et al, 2016) . However, the use of DLI is associated with increased risk of acute GVHD (Mielcarek et al, 2007; Warlick et al, 2012; Takami et al, 2014; He et al, 2016) . Prior reports suggest that the efficacy of the DLI in patients with relapsed AML is higher when performed after cytoreductive chemotherapy, although there is yet no uniformly accepted opinion on which chemotherapy regimens are superior (Mielcarek et al, 2007; Oran et al, 2007; Warlick et al, 2012; Bejanyan et al, 2014; He et al, 2016) . In a European Group for Blood and Marrow Transplantation (EBMT) registry analysis of 399 relapsed AML patients after RIC allo-HCT, of whom 171 received DLI, the use of DLI was associated with significant OS benefit as compared to the untreated group (21% vs. 9% at 2 years; P < 0Á0001) (Schmid et al, 2007) but selection bias regarding patients considered suitable or fit for the preceding chemotherapy confounds this comparison. Chemotherapy prior to DLI was used in 75% of the patients and one-third of patients receiving DLI achieved a CR (Schmid et al, 2007) . Several factors have been associated with improved outcomes after DLI, including female sex, lower bone marrow leukaemia burden (<35% blasts), favourable cytogenetics, and remission prior to DLI. In contrast, acute GVHD after DLI was associated with poor survival, while chronic GVHD was associated with improved outcomes.
Similarly, in a CIBMTR analysis, patients treated with DLI had better survival, with one-third of them surviving 1 year after relapse (Bejanyan et al, 2015) . The majority of these patients (80%) received chemotherapy prior to DLI. While 1-year survival post-relapse in patients treated with DLI was only 13% in those relapsing within 6 months of allo-HCT, it was 35% with relapse between 6 months and 2 years, 50% with relapse between 2 and 3 years and 58% with relapse >3 years after transplantation. This emphasizes that a longer time to relapse may predominate in predicting response to any intervention and that DLI is particularly beneficial in patients who had a longer remission after transplantation. Both in EBMT and CIBMTR studies, a minority of patients treated with DLI subsequently received second allo-HCT. Longer survival (24% beyond 1 year after relapse) in the CIBMTR study was observed in patients who received a second allo-HCT.
Recent efforts have focused on strategies to enhance the GVL effect of DLI or reduce the morbidity of GVHD. Initial studies of donor lymphocyte priming with ex-vivo co-stimulation of donor T cells using anti-CD3 and anti-CD28 coated beads yielded promising results in small series (Porter et al, 2006) . Chemotherapy prior to DLI may reduce the leukaemia burden, but may also have immunomodulatory effects through lymphodepletion, suppression of T regulatory cells and release of cytokines that can enhance GVL activity (Guillaume et al, 2012) . In addition, azacitidine has been shown to enhance GVL activity by increasing tumour immunogenicity (Sanchez-Abarca et al, 2010; Craddock et al, 2016) , and has been administered before DLI to treat relapse (Schroeder et al, 2015; Steinmann et al, 2015; Ghobadi et al, 2016) . A recent retrospective multicentre study by the German Cooperative Transplant Study Group using azacitidine prior to DLI in 154 patients with relapsed AML or MDS after allo-HCT showed that this therapy is well-tolerated and effective, particularly in patients with low disease burden. Overall response was achieved in a third of the patients and overall survival at 2 years was approximately 30%. In multivariate analysis, patients with only molecular relapse and those with MDS had the best chance to achieve remission (Schroeder et al, 2015) . In another study using azacitidine (median 2Á7 cycles) prior to DLI in 65 patients with relapse after allo-HCT, there was temporary control of leukaemia in~45% of patients, but only 10% achieved a CR (Steinmann et al, 2015) . The treatment was well-tolerated, with only 10 of 65 patients developing acute GVHD after DLI. Based on data showing increased numbers of regulatory T cells with administration of azacitidine (Choi et al, 2010; Sanchez-Abarca et al, 2010) , azacitidine after DLI was recently tested in a phase 1 study to prevent development of GVHD (Ghobadi et al, 2016) . Azacitidine was administrated on days 4, 6, 8 and 10 after DLI with dose escalation schedule of 30-75 mg/ m 2 in 39 patients with relapsed AML after allo-HCT. None of the patients developed severe acute GVHD.
Second allogeneic haematopoietic cell transplantation
Second allo-HCT is often considered for patients with relapsed AML after transplantation who are fit enough to tolerate a second transplant. In an EBMT analysis, a second transplant after a first RIC transplantation resulted in a CR rate of 40-55% (Schmid et al, 2012) . Survival at 2 years was only 15% for patients receiving second allo-HCT without prior chemotherapy, while it was 42% for those receiving chemotherapy followed by second allo-HCT. Relapse followed by treatment-related mortality were the main causes of death after second transplantation. In a CIBMTR analysis of 369 patients receiving second allo-HCT, a large majority of patients (80%) received their second allo-HCT within 6 months of relapse with only 44% of all patients achieving a CR (Bejanyan et al, 2015) . Half of patients received myeloablative conditioning with their second allo-HCT. Using a different donor for second transplant had no favourable impact on survival. Almost half of the patients receiving a second allo-HCT were alive at 1 year after relapse. While survival beyond 1 year after relapse was only 32% in patients relapsing within 6 months of first allo-HCT, it was better (55-62%) in those relapsing beyond 6 months from their initial transplantation. These findings support consideration of second allo-HCT for those patients who have later relapses after the first transplantation and that the GVL benefit of cell-based therapy is strongest in those with a longer remission from the initial allo-HCT.
Small molecules
FLT3 inhibitors
Approximately 30% of AML patients harbour a ligand-independent activating mutation in the gene encoding FMS-like tyrosine kinase 3 (FLT3) (Gilliland & Griffin, 2002) , associated with high risk of relapse and poor prognosis (Rombouts et al, 2000; Kottaridis et al, 2001; Fr€ ohling et al, 2002; Thiede et al, 2002) . Several FLT3 inhibitors have been developed and tested in clinical trials in various settings (e.g. frontline, relapsed/refractory, maintenance, transplant or non-transplant setting, as single agent or in combination with other therapies) (Fathi & Chen, 2017) . These agents vary in their specificity, potency and side effects, and many lessons are still to be learned about their place in upfront, salvage, and maintenance settings. The role of FLT3 inhibitors in the treatment of FLT3-mutated AML has been exhaustively reviewed (Fathi & Chen, 2017) . Here, we briefly highlight the most important results from prospective studies in the relapsed/refractory setting.
Single agent. Only one study using sorafenib [with activity specific to the FLT3 internal tandem duplication (ITD) mutation] as single agent in the relapsed/refractory setting has been published. In this phase 1 study (n = 50, including 6 previously untreated patients, median age 61 years, including 8 post-transplant cases), an ORR of 44% was observed although only 10% of patients achieved a CR/CRi (Borthakur et al, 2011) . A phase 1/2 study of 252 relapsed/refractory patients (median age 62 years; including 58 FLT3 wild-type patients) used Gilteritinib (ASP2215), a highly selective FLT3 inhibitor, and achieved an ORR of 57% in FLT3-mutated patients (Perl et al, 2016) . A phase 2 study of 34 relapsed/refractory FLT3-mutated patients (median age 61 years) used crenolanib and achieved an ORR of 47% (CRi 12%), with a median event-free survival (EFS) of 8 weeks (Randhawa et al, 2014) . Quizartinib (AC220) monotherapy in 90 relapsed/refractory FLT3-ITD patients resulted in an ORR of 74% (CR/ CRi 53%) (Levis et al, 2012) . A recently completed, but not reported, randomized study is seeking the optimal dose of quizartinib in FLT3-mutated relapsed/refractory patients (NCT01565668). QuANTUM-R (NCT02039726) is an ongoing randomized study of quizartinib versrs conventional chemotherapy as salvage for relapsed/refractory FLT3-ITD patients. A randomized phase 2 study of midostaurin (PKC412) compared two doses of this FLT3 inhibitor (50 or 100 mg twice daily) in 35 relapsed/refractory FLT3-mutated patients and achieved an ORR of 67% including patients with haematological improvement and blast response (Fischer et al, 2010) .
In combination with HMAs. In a phase 2 study of 37 evaluable patients (median age 64 years, including 7 post-transplant and 6 frontline cases) treated with sorafenib plus azacitidine, CR/CRi rate was 43%, with a median EFS of 3Á8 months (Ravandi et al, 2013) . Based on these results and those from other reports, synergism between sorafenib and HMAs is possible. Whether specific subsets of patients (e.g. TP53-mutated, complex karyotype) respond better to this combination remains to be studied. Midostaurin has been combined with azacitidine, although the study included both FLT3-mutated and wild-type patients as well as both untreated and relapsed/ refractory patients (Strati et al, 2015) . Crenolanib is being studied as combination with azacitidine in FLT3-mutated relapsed/refractory patients (NCT02400281).
In combination with chemotherapy. Lestaurtinib (CEP701) was compared in combination with chemotherapy to chemotherapy alone in a randomized trial (n = 112 in each arm) of FLT3-mutated patients in first relapse (Levis et al, 2011) . CR/CRp (complete remission with or without platelet recovery) rates in the experimental arm was 26%, with no significant difference from controls. Crenolanib is being studied as combination with salvage chemotherapy in FLT3-mutated AML (NCT02626338 and NCT02400281). In a planned placebo-controlled double-blinded randomized phase 3 study, relapsed/refractory FLT3-mutated patients will receive salvage chemotherapy alone or followed by crenolanib (NCT02298166).
As maintenance therapy post-transplant. A phase 1 study of 22 patients with FLT3-ITD disease (median age 53 years) showed an maximum tolerated dose of 400 mg twice daily for sorafenib, with impressive 1-year post-HCT disease-free survival and OS rates of 85% and 95%, respectively (Chen et al, 2014) . Grade II-IV acute GVHD occurred in only one patient. Treatment in this study started between days 45 and 120 post-HCT (median: 70 days). It has been suggested that sorafenib has both cytotoxic and maturating effects on leukaemic cells (Liegel et al, 2014) , and these effects may potentiate or synergize with the GVL effect (Mathew et al, 2016) . Crenolanib is being studied as post-HCT maintenance in FLT3-mutated patients (NCT02400255). Collectively, FLT3 inhibitors have been a useful and promising addition to our armamentarium and the listed studies, among others, will collectively determine the optimal setting(s) and combinations for using these novel drugs. Future work will further clarify any potential long-term toxicities, especially in the post-transplant maintenance setting. Finally, the preferred duration of treatment with FLT3 inhibitors (short-term vs. long-term vs. indefinite) after molecular remission is unknown.
IDH inhibitors
Isocitrate dehydrogenase (IDH) mutations occur in about 10-20% of AML patients (DiNardo et al, 2015) . Although these mutations do not appear to be independently prognostic, small molecule inhibitors may be used for disease debulking. Enasidenib, an oral IDH2 inhibitor recently granted approval by the US Food and Drug Administration (FDA), was tested in a single-arm study of 176 IDH2-mutated adult patients with relapsed/refractory AML. When given orally at a dose of 100 mg daily, the CR rate was 19% with a median remission duration of 6 months. Importantly, the median time to best response was 2 months, in contrast with intensive chemotherapy. The most common side effects were gastrointestinal, but a unique early differentiation syndrome with an initial increase in blast count was also observed (Stein et al, 2017) . A phase 3 randomized study (IDHENTIFY) is currently comparing AG-221 with physicians' choice in older patients (age ≥ 60 years) with relapsed/ refractory IDH2-mutated AML (NCT02577406). Several other IDH inhibitors are being tested in early-phase clinical trials but the results are not yet available.
Other small molecules
Murine double minute 2 (MDM2) is a physiological antagonist of TP53 and causes cell cycle arrest or apoptosis of TP53-wild type AML cells. In a phase Ib study of 23 relapsed/refractory AML patients, Idasanutlin in combination with cytarabine resulted in a CR/composite CR (CR+CRp+CRi; CRc) rate of 54% . This combination is being tested in a phase 3 randomized study (NCT02545283). Venetoclax, a BCL2 antagonist, activates the mitochondrial pathway of apoptosis, not only in chronic lymphocytic leukaemia cells (where it was first studied) but also AML cells (Pan et al, 2014) . In a phase 2 study of relapsed/refractory (n = 30) or unfit patients (n = 2), venetoclax resulted in a CR/CRi rate of 19% (Konopleva et al, 2016) . Selinexor, a selective inhibitor of nuclear export (SINE), was used in combination with decitabine and resulted in a 21% CR/CRi/marrow CR in a phase 1 trial of 19 relapsed/refractory patients (Bhatnagar et al, 2016) . As a single-agent, this drug showed modest activity in a phase I clinical trial of 95 relapsed/refractory AML patients, with an objective response rate of 14% (Garzon et al, 2017) .
Strategies targeting the microenvironment
Acute myeloid leukaemia cells are in anatomic and functional interaction with cellular and acellular structures of the bone marrow niche, where they reside (Schofield, 1978) . These interactions have critical roles in AML development, progression, response to therapy and relapse. Several approaches targeting the AML-niche interaction have been developed and tested in preclinical phase and clinical trials (Rashidi & Uy, 2015; Rashidi & DiPersio, 2016) . The most successful and extensively studied agent in this category is plerixafor (AMD3100), a small molecule inhibitor of CXCR4. CXCR4 is a G-protein coupled chemokine receptor expressed on the surface of haematopoietic stem cells (as well as AML blasts; M€ ohle et al, 1998) and interacts with CXCL12 (produced by the marrow stroma and endothelial cells) (Sugiyama et al, 2006) . The signalling resulting from this interaction promotes homing of haematopoietic stem cells (and probably AML cells) to the marrow in response to CXCL12 gradients. By disrupting AML-niche interactions, plerixafor mobilizes leukaemic cells out of their protective niches and exposes them to concurrently administered chemotherapy. In a phase I/II study of 52 relapsed/refractory AML patients, plerixafor in combination with multi-agent chemotherapy doubled AML cell mobilization from the marrow and resulted in an encouraging CR/CRi rate of 46% (Uy et al, 2012) . A combination of filgrastim, plerixafor, and sorafenib in patients with relapsed/refractory FLT3-ITD AML resulted in an ORR of 62% (CR/CRp 28%) (Andreeff et al, 2012) .
Tumour hypoxia contributes to chemoresistance and has been a potential target for novel therapies to enhance the sensitivity of AML cells to chemotherapy. By releasing the DNA alkylating agent bromo-isophosphoramide mustard under hypoxic conditions of the marrow niche, evofosfamide (TH-302) has hypoxia-dependent cytotoxic effects on acute leukaemia cells. In a phase I study of TH-302 in combination with chemotherapy in 39 relapsed/refractory AML patients, only two patients achieved a CR/CRi and responses were transient (Badar et al, 2016) .
Immunotherapy
Immunotherapy in AML has not advanced as fast as in other areas of oncology. This may partially be due to the fact that AML is not a genomically (and perhaps antigenically) complex disease (The Cancer Genome Atlas Research Network, 2013) . Nonetheless, immunotherapy is a very active field of investigation in AML and we review the few remarkable clinical results.
Antibody-drug conjugates
Gemtuzumab ozogamicin (GO) is the first and, to date, the only FDA-approved immunotherapy approach in AML. The approval of this anti-CD33 monoclonal antibody conjugated with cytotoxic calicheamicin, was based on a study of 142 CD33-positive AML patients in first relapse (Bross et al, 2001; Sievers et al, 2001) . Treatment resulted in an ORR of 30% (CR 16%), but was associated with a unique toxicity (hepatic sinusoidal obstructive syndrome). GO is the only immunotherapy modality that has provided a survival benefit in randomized clinical trials (Rashidi & Walter, 2016) . After an initial withdrawal from the US market in June 2010, GO is now (September 2017) re-approved in the US and commercially available. Currently approved indications for GO are in (i) adults with newly diagnosed CD33-positive AML and (ii) relapsed/refractory CD33-positive AML patients aged 2 years and older. SGN-CD33A (vadastuximab talirine), is another CD33 antibody-drug conjugate that uses a more potent cytotoxic compound (pyrrolobenzodiazepine dimer) than calicheamicin. Early results of a phase I trial with this drug in 93 AML patients (including 13 previously untreated patients) showed a CR/CRi of 33% at the 40 lg/kg dose level (Stein et al, 2015) . However, ongoing clinical trials with this agent were discontinued in mid 2017.
Other approaches
Other immunotherapy approaches, such as bispecific T-cell engagers (BiTEs), dual affinity retargeting agents (DARTs), chimeric antigen receptor (CAR) T cells, radioimmunoconjugates, immunotoxins, cell-based vaccines and checkpoint inhibitors, are being extensively studied in AML patients, some with promising preclinical results, but the clinical results are still preliminary. In a phase 2 study of haploidentical natural killer (NK) cell infusion following lymphodepleting chemotherapy and interleukin-2 (IL2) diphtheria toxin (IL2DT; to eliminate regulatory T cells and augment NK cell expansion), and post-HCT IL2 in 15 patients with relapsed/refractory AML, a CRc rate of 53% was achieved at day 28 post-NK cell infusion. In a cohort of 42 patients who were treated using the same protocol but without IL2DT, the CRc rate was significantly lower (21%), supporting the role of Treg depletion to increase NK cell expansion and their anti-leukaemic effect (Bachanova et al, 2014) .
Conclusions
After a few decades of relative stasis in new therapies for relapsed/refractory AML, finally there are numerous novel approaches and medications being developed and are in various stages of testing in clinical trials. The studies ongoing with these new agents will probably significantly change how we will treat relapsed/refractory AML in the next 5-10 years. For now, when seeing a patient with relapsed/refractory disease, the single best treatment is allo-HCT in CR after salvage therapy (if the patient has not previously undergone allo-HCT). In the relapsed patient following allo-HCT, cure is currently unlikely, with infrequent exceptions occurring after second transplants or DLI. For salvage treatment, options vary from traditional cytotoxic chemotherapy to small molecules, niche-targeting agents, and a rapidly expanding list of immunotherapeutic approaches. The greatest advance has arguably been made with FLT3 inhibitors, potentially applicable as second line, bridge to transplant, maintenance after transplant, and even salvage after post-HCT relapse. Enasidenib and GO recently received FDA approval for use as salvage therapy in IDH2-mutated and CD33-positive AML patients. Post-transplant maintenance for high-risk patients is one focus of high attention and the subject of many ongoing trials.
Our first question when deciding for the next line of therapy for relapsed/refractory patients is whether there is a welldesigned clinical trial. If there is one, we try to enrol the patient. Otherwise, we look for targetable genomic derangements, some of which (e.g., FLT3) can be identified very quickly. We offer patients the appropriate small molecules inhibitors, typically in the context of clinical trials, but sometimes via compassionate use mechanisms. For fit patients, we search for suitable allogeneic donors and, as soon as allo-HCT is possible (i.e., donor identified, disease in remission, and patient ready), we proceed to allo-HCT with curative intent. For post-transplant relapse, we taper the immunosuppressive medications, consider DLIs (typically after chemotherapy or HMAs for tumour debulking), and include an appropriate small molecule inhibitor if a targetable mutation is found. 
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